FIELD: biotechnology.
SUBSTANCE: described is a method of producing a binding polypeptide conjugated with an effector group (embodiments). In one embodiment, the method involves producing a modified glycan by treating a natural or engineered glycan binding polypeptide with sialyltransferase and/or galactosyltransferase, reaction of the terminal sialic acid residue and/or galactose residue with an oxidising agent and subsequent reaction of the oxidised sialic acid residue and/or the oxidised galactose residue with an effector group.
EFFECT: invention extends the range of methods for producing a binding polypeptide conjugated with an effector group.
24 cl, 36 dwg, 16 tbl, 15 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TRISPECIFIC BINDING MOLECULES FOR TREATING VIRAL HEPATITIS B INFECTION AND BOUND STATES | 2016 |
|
RU2733496C2 |
| BISPECIFIC 2+1 ANTIBODIES | 2018 |
|
RU2797305C2 |
| IMPROVED ANTIGEN-BINDING RECEPTORS | 2018 |
|
RU2825816C2 |
| DELIVERY OF THERAPEUTIC POLYPEPTIDES VIA PSEUDOTYPED ONCOLYTIC VIRUSES | 2017 |
|
RU2758007C2 |
| VARIANTS OF FC-REGION WITH MODIFIED ABILITY TO BIND TO FCRN AND WITH PRESERVED ABILITY TO BIND WITH PROTEIN A | 2015 |
|
RU2727639C2 |
| MUTANT VARIANTS OF Fc IgG1 DEVOID OF EFFECTOR FUNCTIONS | 2018 |
|
RU2764559C2 |
| VERSIONS OF THE FC-DOMAIN WITH MODIFIED ABILITIES TO BIND TO FCRN | 2015 |
|
RU2730592C2 |
| BISPECIFIC BINDING PROTEINS AND APPLICATION WAYS THEREOF | 2017 |
|
RU2766199C2 |
| CSF1R-BASED CHIMERIC PROTEINS | 2018 |
|
RU2792239C2 |
| CHIMERIC PROTEINS BASED ON TIGIT AND LIGHT | 2018 |
|
RU2775490C2 |
